Enfuvirtide Peptide: Fuzeon, T-20, HIV gp41 Fusion Inhibitor
Enfuvirtide (Fuzeon, T-20) is an approved 36-mer HIV-1 gp41 fusion inhibitor. Guide to mechanism, TORO trial evidence, dosing and injection-site safety.
Enfuvirtide is a peptide drug with a very different evidence profile from research-market "antiviral" peptides. It is a synthetic 36-amino-acid peptide, the first approved HIV-1 fusion inhibitor, sold under the brand name Fuzeon and known during development as T-20.
The key context is that enfuvirtide is a fully approved prescription antiretroviral, not an experimental or wellness compound. It was reviewed by the FDA, studied in large randomized trials, and carries a detailed prescribing label. That label, not a generic "peptide protocol," defines how it is used.
For related peptide-pharmacology context, compare this guide with the icatibant bradykinin antagonist, the octreotide somatostatin analog, oxytocin, an overview of what peptides are, and the peptide half-life guide, which explains why a short-half-life injectable like enfuvirtide is dosed twice daily.
This guide is educational and not medical advice. Enfuvirtide is a prescription medicine for a serious infection. It should be started, monitored, changed or stopped only through qualified HIV care.
Enfuvirtide At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | A synthetic 36-amino-acid peptide HIV-1 fusion (entry) inhibitor, brand name Fuzeon, development code T-20. |
| Drug class | First-in-class HIV-1 gp41 fusion inhibitor, an antiretroviral. |
| Main target | The HR1 region of the gp41 envelope glycoprotein subunit of HIV-1. |
| Approval status | FDA accelerated approval March 13, 2003; approved, not investigational. |
| Labeled indication | With other antiretrovirals, for HIV-1 in treatment-experienced patients with ongoing viral replication. |
| Reference dose (per label) | Adults 90 mg subcutaneously twice daily; not a recommendation, see a clinician. |
| Main safety frame | Near-universal injection-site reactions plus systemic warnings. |
How A Fusion Inhibitor Blocks HIV Entry
HIV-1 enters a CD4+ cell through a multi-step membrane-fusion process driven by the viral envelope glycoprotein. After the gp120 subunit engages CD4 and a coreceptor, the gp41 subunit drives the actual fusion of the viral and cell membranes. Two regions of gp41, the first heptad repeat (HR1, also called the N-terminal heptad repeat) and the second heptad repeat (HR2), fold together into a six-helix bundle that pulls the two membranes into contact.
Enfuvirtide is a peptide whose sequence is derived from the HR2 region of gp41. Because it looks like the natural HR2 helix, it binds to the exposed HR1 groove during the brief window when gp41 is extended. By occupying HR1, enfuvirtide prevents HR1 and HR2 from zipping together into the six-helix bundle. Without that bundle, the conformational change needed for fusion cannot complete, and the virus cannot enter the cell.
That mechanism is fundamentally different from most other antiretroviral classes. Reverse transcriptase, protease and integrase inhibitors act inside the cell on viral enzymes. Enfuvirtide acts outside the cell, on a structural protein, which is why it remains active against virus that is already resistant to those intracellular drug classes. The FDA prescribing information and peer-reviewed virology work both describe this HR1-binding, anti-fusion mechanism.
Approval And Labeled Use
Enfuvirtide received FDA accelerated approval on March 13, 2003. It was the first HIV fusion inhibitor and the first new antiretroviral class in several years at the time. It was discovered at Trimeris in Durham, North Carolina, and co-developed with Hoffmann-La Roche, with marketing by Genentech in the United States and Roche internationally.
| Item | What the label and trials support | Important limit |
|---|---|---|
| Indication | Combination therapy for HIV-1 in treatment-experienced adults and pediatric patients (at least 6 years) with replication despite ongoing antiretroviral therapy. | It is an add-on to an optimized regimen, not a standalone or first-line monotherapy. |
| Adult dose | 90 mg (1 mL) twice daily, subcutaneous, into the upper arm, anterior thigh or abdomen. | Listed for reference only; this is not dosing advice. |
| Pediatric dose | 2 mg/kg twice daily, up to a 90 mg maximum, for eligible weight ranges. | Pediatric eligibility and dosing are clinician-determined. |
| Formulation | Lyophilized powder reconstituted with sterile water before subcutaneous injection. | Reconstitution and rotation of injection sites follow the label. |
The "treatment-experienced" framing matters. Enfuvirtide was positioned for people whose virus had already escaped multiple oral regimens, where a drug with a novel mechanism could re-suppress otherwise resistant HIV-1.
Clinical Evidence And Its Limits
The pivotal evidence came from two 24-week randomized, controlled, open-label studies, TORO 1 (North and South America) and TORO 2 (Europe and Australia), together enrolling roughly 1,000 treatment-experienced patients. Both compared an optimized background regimen plus enfuvirtide against the optimized background alone. Patients adding enfuvirtide were about twice as likely to reach undetectable plasma HIV-1 RNA and showed greater CD4 cell gains. The TORO 1 results were published in the New England Journal of Medicine in 2003.
The evidence is genuinely strong for what it tested, but it has honest limits. First, the benefit was demonstrated as an add-on to a background regimen, not as monotherapy; enfuvirtide given alone selects resistance quickly because gp41 can mutate in the HR1 binding region. Second, the trials were 24 weeks, focused on a heavily treatment-experienced population of that era. Third, the practical burden of twice-daily injections, plus injection-site reactions, limited long-term real-world use as newer oral agents arrived. Enfuvirtide remains approved, but it is now used selectively rather than as a routine option.
Pharmacology And Half-Life
Following a single 90 mg subcutaneous dose, the FDA label reports a mean elimination half-life of about 3.8 hours (3.8 plus or minus 0.6 h). That short half-life is the reason for twice-daily dosing and is why the peptide is given by injection rather than orally. As a large peptide it would be digested in the gut, so subcutaneous delivery is required. This is a useful illustration of the points in the peptide half-life guide: peptide size, route and clearance together dictate the dosing schedule, and a short half-life means missed-dose timing genuinely matters.
Safety Limits
Enfuvirtide's safety story is dominated by where and how it is given, plus a few systemic warnings from the label and pooled trial data.
| Safety issue | Why it matters |
|---|---|
| Injection-site reactions | Nearly all users experience them; in TORO data about 98% had at least one, including erythema, induration, nodules and cysts. |
| Bacterial pneumonia | Pooled TORO data showed a higher rate of bacterial pneumonia in enfuvirtide-treated patients; clinicians monitor for respiratory symptoms. |
| Systemic hypersensitivity | Rare but reported reactions can include rash, fever, vomiting, respiratory distress and renal involvement, and may recur on rechallenge. |
| False-positive HIV antibody test | Anti-enfuvirtide antibodies can cross-react with gp41, potentially giving a false-positive HIV ELISA; confirmatory testing is expected negative. |
| Resistance | Mutations in the gp41 HR1 region reduce susceptibility, so it must be used within a suppressive combination regimen. |
| Local nerve and skin effects | Injection-site nodules, infection and rare neuralgia have been described. |
Enfuvirtide can also cause more general effects seen across HIV therapy contexts, including fatigue, nausea and lab changes, and immune reconstitution inflammatory syndrome can occur as the immune system recovers. The detailed, current list belongs to the prescribing information and the treating clinician.
How To Evaluate An Enfuvirtide Claim
Because "antiviral peptide" is a popular marketing phrase, it helps to apply a few checks before trusting any claim about enfuvirtide.
First, is the source distinguishing the approved drug Fuzeon from generic "T-20 peptide" products sold for research use? Approval applies to the regulated medicine, not to gray-market vials.
Second, does the claim respect the indication? Enfuvirtide is for treating established HIV-1 in treatment-experienced patients, used in combination. It is not a prophylactic, not a cure, and not a general "immune" or "longevity" peptide.
Third, does it mention the injection burden and the near-universal injection-site reactions? A source that omits these is presenting an incomplete picture.
Fourth, does it acknowledge resistance and the need for a background regimen? Claims of standalone antiviral power ignore how quickly gp41 escapes a single agent.
Fifth, is prescription-label evidence being used to imply unsupervised human use? That is the same red flag that applies to any approved peptide repurposed for the self-experimentation market. The same caution applies to other approved peptides such as octreotide or teduglutide: approval is for a defined medical indication, not open-ended use.
Bottom Line
Enfuvirtide is a real, FDA-approved peptide medicine with a clear, well-evidenced role: blocking HIV-1 entry by binding the gp41 HR1 region and preventing membrane fusion. The TORO trials showed it could re-suppress resistant virus when added to an optimized regimen, and it earned approval as the first HIV fusion inhibitor in 2003.
The same profile sets its limits. Enfuvirtide requires twice-daily subcutaneous injection because of its roughly 3.8-hour half-life, causes injection-site reactions in almost everyone, must be combined with other active drugs to avoid rapid resistance, and carries systemic warnings including bacterial pneumonia and hypersensitivity. It is a targeted, clinician-managed antiretroviral, not a casual antiviral peptide.
References
U.S. FDA. Fuzeon (enfuvirtide) for Injection, Highlights of Prescribing Information (2018).
U.S. FDA. Fuzeon (enfuvirtide) for Injection, original 2003 label.
Lalezari JP, et al. Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America (TORO 1), N Engl J Med 2003.
Oldfield V, et al. Enfuvirtide: a review of its use in the management of HIV infection.
Matthews T, et al. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection.
NIH LiverTox. Enfuvirtide (LiverTox: Clinical and Research Information on Drug-Induced Liver Injury).
NIH Clinicalinfo HIV. Enfuvirtide (T-20, Fuzeon) pediatric antiretroviral information.
Pang W, et al. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.